UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $5.03 Million Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 9.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 113,229 shares of the biopharmaceutical company’s stock after selling 12,241 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.20% of Agios Pharmaceuticals worth $5,031,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Farallon Capital Management LLC boosted its position in Agios Pharmaceuticals by 1.1% in the second quarter. Farallon Capital Management LLC now owns 5,654,502 shares of the biopharmaceutical company’s stock valued at $243,822,000 after buying an additional 63,900 shares in the last quarter. Marshall Wace LLP lifted its stake in shares of Agios Pharmaceuticals by 307.8% in the 2nd quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock valued at $48,887,000 after acquiring an additional 855,739 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its holdings in shares of Agios Pharmaceuticals by 66.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 871,974 shares of the biopharmaceutical company’s stock valued at $37,600,000 after acquiring an additional 348,808 shares in the last quarter. Fisher Asset Management LLC grew its position in Agios Pharmaceuticals by 20.5% during the 3rd quarter. Fisher Asset Management LLC now owns 855,328 shares of the biopharmaceutical company’s stock worth $38,002,000 after acquiring an additional 145,416 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. increased its holdings in Agios Pharmaceuticals by 87.3% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 678,234 shares of the biopharmaceutical company’s stock worth $29,245,000 after purchasing an additional 316,100 shares in the last quarter.

Insider Activity at Agios Pharmaceuticals

In related news, CFO Cecilia Jones sold 2,542 shares of the stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the transaction, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at $988,346.74. This represents a 11.20 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.93% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Leerink Partnrs cut Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Royal Bank of Canada boosted their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Friday, September 20th. StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Finally, Leerink Partners downgraded Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $60.00 to $56.00 in a report on Friday, September 27th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $56.33.

Agios Pharmaceuticals Trading Down 5.8 %

Shares of AGIO opened at $43.37 on Thursday. The firm’s fifty day simple moving average is $50.12 and its two-hundred day simple moving average is $46.65. Agios Pharmaceuticals, Inc. has a 12 month low of $20.96 and a 12 month high of $62.58. The stock has a market capitalization of $2.47 billion, a P/E ratio of 3.82 and a beta of 0.80.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.